The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.
The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.
REGENXBIO: DMD Program Lends Additional Credibility To NAV Technology Platform (RGNX) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.